Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations

Neha Mehta, Alan S. Wayne, Youn H. Kim, Gregory A. Hale, Carlos S. Alvarado, Patricia Myskowski, Elaine S. Jaffe, Klaus J. Busam, Melissa Pulitzer, Jeffrey Zwerner, Steven Horwitz

Research output: Contribution to journalArticlepeer-review

60 Scopus citations

Abstract

Introduction: Subcutaneous panniculitis-like T-cell lymphoma (SPTL-AB) and cutaneous gamma/delta T-cell lymphoma (CGD-TCL) are rare T-cell lymphomas with varying clinical courses. There is no standard treatment, although chemotherapy and hematopoietic stem cell transplantation are commonly used. We describe results using bexarotene for children and adults with these disorders. Methods: We identified 15 patients (12 adults, 3 children) who were treated with bexarotene between 2000 and 2010 from the Memorial Sloan-Kettering Cancer Center lymphoma database, the Stanford Cancer Center Registry, and the National Cancer Institute (NCI) pediatric lymphoma database. There were 8 females and 7 males, with a median age of 45 years (range, 3 years to 85 years). All patients had stage IV disease. Two of 15 and 4 of 15 patients had documented CGD-TCL and SPTL-AB, respectively; others were presumed to have SPTL-AB. Bexarotene was administered at flat doses corresponding to 91 to 339 mg/m 2/d. Two of 15 patients received concurrent denileukin diftitox. Two children received bexarotene as maintenance therapy and were not evaluable for response. Results: Among those treated with bexarotene alone, the overall response rate (ORR) was 82% (6/11 complete response [CR], 3/11 partial response [PR]). One of the 2 patients treated with concomitant denileukin diftitox responded for an ORR of 10/13 (77%), including 54% CR and 23% PR. Median progression-free survival was 38.4 months; median duration of response was 26.3 months. Six patients developed hypothyroidism and 9 developed hyperlipidemia; one patient developed dose-limiting hypertriglyceridemia. One pediatric patient developed insulin-dependent diabetes mellitus. Conclusions: In this retrospective series, bexarotene showed a high response rate in SPTL-AB and CGD-TCL. It was generally well-tolerated with durable responses; therefore, bexarotene represents a promising therapy for children and adults with these disorders.

Original languageEnglish
Pages (from-to)20-25
Number of pages6
JournalClinical Lymphoma, Myeloma and Leukemia
Volume12
Issue number1
DOIs
StatePublished - Feb 2012

Keywords

  • Bexarotene
  • Cutaneous gamma/delta T-cell lymphoma
  • Subcutaneous panniculitis-like T-cell lymphoma

Fingerprint

Dive into the research topics of 'Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations'. Together they form a unique fingerprint.

Cite this